EBITDA: Income before interest, taxes, depreciation and amortization.
Vivos Therapeutics, Inc. (VVOS) had EBITDA of $-5.93M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
$3.82M |
|
$-6.89M |
|
$0.84M |
|
$2.99M |
|
$10.20M |
|
$-6.38M |
|
$-0.58M |
|
$-6.95M |
|
$-6.95M |
|
$-6.95M |
|
$-6.95M |
|
$-6.95M |
|
$-6.95M |
|
$-6.38M |
|
|
EBITDA |
$-5.93M |
10.27M |
|
10.27M |
|
$-0.58 |
|
$-0.58 |
|
| Balance Sheet Financials | |
$4.38M |
|
$3.76M |
|
$20.77M |
|
$25.15M |
|
$18.08M |
|
$0.47M |
|
$8.63M |
|
$26.70M |
|
$-1.43M |
|
$-14.17M |
|
$-1.55M |
|
9.29M |
|
| Cash Flow Statement Financials | |
$-15.26M |
|
$-7.53M |
|
$18.56M |
|
$6.26M |
|
$2.03M |
|
$-4.23M |
|
$0.66M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.24 |
|
-- |
|
-- |
|
-0.43 |
|
-5.69 |
|
78.09% |
|
-166.76% |
|
-166.76% |
|
-- |
|
-181.83% |
|
-180.26% |
|
$-17.60M |
|
-- |
|
-- |
|
-- |
|
0.15 |
|
-- |
|
2.42 |
|
37.21 |
|
486.22% |
|
49.08% |
|
-27.64% |
|
643.20% |
|
$-0.17 |
|
$-1.71 |
|
$-1.49 |
|